Updated Jul 16, 2026
Gagnon Robert E. has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $45K.
Robert E. Gagnon is a corporate executive known for his roles as Director and Chief Financial Officer at various companies, including Verastem, Inc. and Harvard Bioscience Inc. He has been involved in SEC filings related to these companies, indicating his active participation in corporate governance.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-11 | HBIO | HARVARD BIOSCIENCE INC | A — Grant or award | 16.6K | $0.00 | |
| 2026-04-27 | IRD | Opus Genetics, Inc. | S — Open-market sale | 7.8K | $5.18 | $41K |
| 2026-01-27 | IRD | Opus Genetics, Inc. | A — Grant or award | 400.0K | $0.00 | |
| 2025-09-16 | VSTM | Verastem, Inc. | S — Open-market sale | 281 | $9.99 | $3K |
| 2025-09-02 | IRD | Opus Genetics, Inc. | A — Grant or award | 200.0K | $0.00 | |
| 2025-07-16 | HBIO | HARVARD BIOSCIENCE INC | A — Grant or award | 110.0K | $0.00 | |
| 2024-12-20 | VSTM | Verastem, Inc. | S — Open-market sale | 130 | $4.37 | $568 |
| 2024-12-20 | VSTM | Verastem, Inc. | S — Open-market sale | 285 | $4.54 | $1K |
Robert E. Gagnon is a corporate executive known for his roles as Director and Chief Financial Officer at various companies, including Verastem, Inc. and Harvard Bioscience Inc. He has been involved in SEC filings related to these companies, indicating his active participation in corporate governance.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($45K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Gagnon Robert E. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.